TECHWIRE 30
(CIX: WRAL30)  990.01  up arrow+8.5  (0.87 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Apple)  519.01  up arrow+1.05  (0.2 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: QUINTILES)  50.60  down arrow-0.07  (-0.14 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: BASF SE)  108.14  up arrow+1.55  (1.45 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioCryst)  8.34  up arrow+0.01  (0.12 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioDelivery)  7.40  up arrow+0.27  (3.79 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: CEMP)  9.23  up arrow+0.5  (5.73 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cisco Systems)  23.03  up arrow+0.14  (0.61 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  56.38  up arrow+0.87  (1.57 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: DARA)  2.48  down arrow-0.02  (-0.8 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: EMC CORPORATION)  26.70  down arrow-0.22  (-0.82 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Extreme Networks)  5.62  down arrow-0.03  (-0.53 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Facebook)  59.72  up arrow+0.63  (1.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: GLAXOSMITHKLINE)  52.82  up arrow+0.5  (0.96 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: GOOG)  556.54  up arrow+20.1  (3.75 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: IBM)  196.40  down arrow-0.62  (-0.31 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NY: LH)  101.95  up arrow+0.39  (0.38 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Lenovo Group)  24.14  up arrow+0.74  (3.17 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: MRK)  56.26  up arrow+0.21  (0.37 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Microsoft Corp)  40.40  up arrow+0.65  (1.64 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: NetApp)  36.24  down arrow-0.76  (-2.04 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: NOVARTIS AG)  84.41  up arrow+0.62  (0.74 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Novozymes A/S)  44.91  up arrow+1.25  (2.86 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: PFIZER)  30.09  up arrow+0.2  (0.67 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Pozen)  8.73  up arrow+0.26  (3.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: RED HAT)  50.62  up arrow+0.52  (1.04 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: BBRY)  7.15  down arrow-0.06  (-0.83 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Salix)  100.66  up arrow+2.47  (2.52 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: SQI)  26.00  up arrow+0.97  (3.88 %)  Updated: 08:10 PM EDT, Apr 16 2014

Posts tagged “Video game industry”

Updated October 13, 2008

Premium Lock BioDelivery Sciences promotes exec to chief technology spot

Niraj Vasisht is the new chief technical officer at BioDelivery Sciences International .

April 2, 2008

Premium Lock BioDelivery Sciences Receives $2.5 Million at Milestone

Meda AB Files for European Approval of BEMA™ Fentanyl

Updated January 15, 2008

Premium Lock BioDelivery Sciences to Expand Research for Breakthrough Pain Drug

BDSI Combination of narcotic, oral lozenge could be used to treat pain caused by other ailments beyond cancer.

Updated November 2, 2007

Premium Lock BioDelivery Sciences Moves HQ to Raleigh

BDSI Move to larger space made to accommodate more employees, company says.

Updated November 1, 2007

Premium Lock BioDelivery Sciences Files Application for Acute Pain Treatment

BDSI Morrisville-based company seeks FDA approval for ‘breakthrough cancer pain.’ BDSI hopes to launch sales in 2008.

September 10, 2007

Premium Lock BioDelivery Sciences to Pay $7M for Ownership of Drug Delivery technology

BDSI RTP-based firm buys all U.S. rights to oral delivery method from QLT USA.

Updated September 5, 2007

Premium Lock What a Relief: BDSI Lands $60M Deal for Rights to Cancer Pain Reliever

 Europe-based Meda pays Morrisville drug development firm $30M up front for North America rights. Meda had already secured European rights.

Updated July 3, 2007

Premium Lock Application Process for Cancer Drug on Target

BioDelivery Sciences International announced Monday that its June 28 pre-NDA meeting with the U.S. Food and Drug Administration regarding the company’s Phase III BEMA Fentanyl product went according to plan.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll